Variations in Amoxicillin Pharmacokinetic/Pharmacodynamic Parameters May Explain Treatment Failures in Acute Otitis Media
- 1 August 2009
- journal article
- research article
- Published by Springer Nature in Pediatric Drugs
- Vol. 11 (4) , 243-249
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) modeling and Monte Carlo simulations suggest that amoxicillin should rarely fail as therapy for Streptococcus pneumoniae and Haemophilus influenzae acute otitis media (AOM) infections except when the S. pneumoniae are highly penicillin resistant or the H. influenzae are β-lactamase producing. However, important and not infrequent exceptions to this expectation have been described. The objective of this review was to define the biologic variations in amoxicillin PK/PD parameters for the treatment of AOM in children and assess whether these variations could explain why the commonly employed amoxicillin PK/PD model is imperfect in predicting outcome for every patient in this clinical setting. To this end, a literature search of MEDLINE (1966–2006) and EMBASE (1974–2006) was conducted to identify studies that evaluated ampicillin or amoxicillin intestinal absorption, serum concentrations, and/or middle ear fluid (MEF) concentrations. Analysis of studies identified for review showed that the intestinal bioavailability of amoxicillin depends on passive diffusion and a saturable ‘pump’ mechanism that produces variable serum concentrations of the antibacterial agent. Indeed, substantial differences from patient to patient in serum (5- to 30-fold) and MEF (up to 20-fold) concentrations of amoxicillin occur following oral administration, and 15–35% of children have no detectable amoxicillin in MEF. These findings suggest that variability in PK/PD parameters may impact amoxicillin concentrations in serum and MEF, possibly explaining some AOM treatment failures.Keywords
This publication has 44 references indexed in Scilit:
- Optimizing Therapy with Antibacterial AgentsPediatric Drugs, 2007
- Molecular interactions between dipeptides, drugs and the human intestinal H+–oligopeptide cotransporter hPEPT1The Journal of Physiology, 2006
- New Formulations of Amoxicillin/Clavulanic AcidClinical Pharmacokinetics, 2005
- Alterations of Penicillin-Binding Proteins 1A, 2X, and 2B in Streptococcus pneumoniae Isolates for Which Amoxicillin MICs Are Higher than Penicillin MICsAntimicrobial Agents and Chemotherapy, 2004
- Verelan PMThe American Journal of Medicine, 2004
- Antibacterial Effects of Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae Strains for Which MICs Are High, in an In Vitro Pharmacokinetic ModelAntimicrobial Agents and Chemotherapy, 2004
- Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious DiseasesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulationThe Pediatric Infectious Disease Journal, 2003
- Measurement of Cefaclor and Amoxicillin-Clavulanic Acid Levels in Middle-Ear Fluid in Patients with Acute Otitis MediaAntimicrobial Agents and Chemotherapy, 2003
- Pharmacologic Studies of Amoxicillin in Nonfasting AdultsThe Journal of Infectious Diseases, 1974